Amgen Inc.

The provided transcript from the Amgen Q4 2020 earnings call does not explicitly mention any current or future plans for fundraising through debt or equity. Key points relevant to capital and financial strategy include: - The company acknowledges intense capital flow into the biotech sector and emphasizes the importance of execution. - Amgen intends to continue growing volumes and after-tax cash flows as underlying objectives. - The focus is on maintaining flexibility with external investment opportunities. - No specific announcements or plans were disclosed regarding raising capital via debt or equity during this call. In summary, no explicit discussion of new fundraising through debt or equity was made in this earnings call transcript.

- Amgen plans to increase R&D investment in 2021, focusing on advancing their pipeline candidates and building differentiated capabilities in early research. - Capital allocation includes continued strong investment in the biosimilars franchise, which remains a competitive margin business and a key allocation of capital. - Ongoing investments in digitization and automation to improve operational productivity and efficiencies. - Building capabilities in human genetics and proteomics through adding large databases and pioneering large-scale proteomic measurements. - Strategic focus on induced proximity platform (targeted protein degradation and beyond) as a long-term research area, to expand druggable targets. - Possible external investment opportunities and acquisitions are part of the capital strategy to support growth and innovation. - Commitment to ESG initiatives including achieving carbon neutrality by 2027 and reduction in waste, reflecting strategic capital deployment in sustainability.

- 2021 revenue guidance: $25.8 billion to $26.6 billion, reflecting volume growth from key products like Prolia, Otezla, Repatha, EVENITY, and innovative oncology portfolio. - Expect mid-single digit decline in net selling prices globally for 2021 due to competition and pricing pressures. - Continued volume growth anticipated for Prolia, Otezla, Repatha, EVENITY, and oncology products. - Growth driven by international expansion, including new launches in Japan, China, Australia, and other emerging markets. - Otezla global growth expected via expanded labeled indications (mild to moderate psoriasis) and international market launches. - Biosimilar sales projected to grow, though offset partially by declining net selling prices due to increased competition. - Digital commercial efforts and product portfolio evolution expected to improve sales force productivity and sustain growth post-COVID. - Continued investment in R&D and pipeline advancement expected to drive future revenue growth.

- Amgen projects 2021 non-GAAP earnings per share guidance in the range of $12.12 to $13.17, reflecting continued growth. - Full year 2020 non-GAAP EPS grew 12% year-over-year; revenue grew 9%. - Operating expenses expected to grow around 7% in 2021 due to investments in innovation and preparations for future launches (e.g., Sotorasib, Tezepelumab). - Amgen targets roughly 50% operating margin in 2021, supported by an industry-leading cost structure. - Mid-single digit global net selling price declines anticipated, with volume growth driving revenue. - Free cash flow strong: $9.9 billion in 2020; capital allocation remains focused on innovation, capital expenditures, dividends, and opportunistic share repurchases (~$4 billion authorized). - Digital and organizational efficiencies expected to support sustained margin and profit growth. - Uncertainty due to COVID-19 vaccination progress may cause quarter-to-quarter variability.

The provided transcript from Amgen's Q4 2020 earnings call does not explicitly mention current or expected orderbook or pending orders. However, some relevant points related to product demand and growth outlook include: - Strong sales growth in 2020 driven by 15% volume growth. - Expansion of international sales beyond the US, exceeding $6 billion. - Continued growth expected for key products like Otezla, Aimovig, and Kyprolis. - Ongoing regulatory filings and expected launches for new medicines such as Sotorasib and Tezepelumab. - Anticipation of incremental volume gains in the biosimilars business despite competitive pressure. - Investments in digital capabilities to improve commercial operations and customer engagement post-COVID. No direct figures or specifics on orderbook or pending orders were discussed on the call.